The Rockefeller University

License Agreement

This Agreement (this "Agreement")is between The Rockefeller University, a New York nonprofit corporation ("Rockefeller"), and Rosetta Genomics, Ltd., an Israeli corporation ("Company"). This Agreement will become effective on January 10, 2008 (the "Effective Date").

BACKGROUND

Rockefeller owns certain intellectual property developed by Dr. Thomas Tuschl relating to microRNA sequences. Rockefeller also owns certain applications for United States letters patent relating to the intellectual property. Company desires to obtain a nonexclusive license under the patent rights to exploit the intellectual property. Rockefeller has determined that the exploitation of the intellectual property by Company is in the best interest of Rockefeller and is consistent with its educational and research missions and goal.

In consideration of the mutual obligations contained in this Agreement, and intending to be legally bound, the parties agree as follows:

1.	LICENSE

1.1 License Grant. Rockefeller grants to Company and its Affiliates a nonexclusive, world-wide license (the "License") to make, have made, use, import, sell, have sold and offer for sale Licensed Products in the Field of Use during the Term (as such terms may be defined in Sections 1.2 and 5.1). Licensee has no right to sublicense except as set forth in Section 1.5. Rockefeller grants no other rights or licenses.

1.2 Related Definitions.

The term "Affiliate" means a legal entity that is controlling, controlled by or under common control with Company and that has executed either this Agreement or a written Joinder Agreement agreeing to be bound by all of the terms and conditions of this Agreement. For purposes of this Section 1.2, the word "control" means (x) the direct or indirect ownership of more than fifty percent (50%) of the outstanding voting securities of a legal entity, (y) the right to receive fifty percent (50%) or more of the profts or earnings of a legal entity, or (z) the right to determine the policy decisions of a legal entity.

The term "Licensed Products" means products that are made, made for, used, imported, sold, sold for or offered for sale by Company and its sublicensees and that either (i) in the absence of this Agreement, would infringe at least one Valid Claim of the Rockefeller Patent Rights, (ii) use a process or machine covered by a Valid Claim of Rockefeller Patent Rights, or (iii) use, at least in part, any Rockefeller Technical Information covered by a Valid Claim of Rockefeller Patent Rights.

The term "Rockefeller Patent Rights" means all patent rights represented by or issuing from: (a) the United States patent applications listed in Exhibit A; (b) any continuation, divisional and re-issue applications of (a); and (c) any foreign counterparts and extensions of (a) or (b).

Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company's application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

The term "Rockefeller Technical Information" means all the information contained in the patents and the patent applications listed in Exhibit A and any other technical information disclosed or referenced in Exhibit A.

The term "Field Of Use" means the sale and use of research products including use of such products in the provision of services to third parties. Specifically excluded from the Field of Use is any use for diagnostic or therapeutic purposes, whether said use is in vivo or in vitro.

The term "Valid Claim" means a claim in a pending or an issued, unexpired patent within the Rockefeller Patent Rights that (a) has not been finally cancelled, withdrawn, abandoned or rejected by any administrative agency or other body of competent jurisdiction, (b) has not been revoked, held invalid, or declared unpatentable or unenforceable in a decision of a court or other body of competent jurisdiction that is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered unenforceable through disclaimer or otherwise, and (d) is not lost through an interference proceeding, provided, however, that any claim that has been pending for more than five (5) years after Company requests in writing that Rockefeller actively prosecute such claim (in the case of a claim to a specific micro RNA sequence by filing a divisional application specific to such sequence) shall cease to be a Valid Claim unless and until such claim is issued.

1.3 Reservation of Rights by Rockefeller. Rockefeller reserves the right to use, and to permit other entities to use, the Rockefeller Patent Rights for all purposes.

1.4 U.S. Government Rights. The parties acknowledge that the United States government retains rights in intellectual property funded under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including, but not limited to, any applicable requirement that products, which result from such intellectual property and are sold in the United States, must be substantially manufactured in the United States. At the request of Company, and at Company's expense, Rockefeller will assist Company in an effort to obtain a waiver of such requirement.

1.5 Sublicenses. Company shall have no right to grant sublicenses under the license granted herein, unless such sublicense is granted as part of a license along with other substantial technology or patent rights of Licensee. Any such sublicense will be subject to each of the following conditions:

(a) In each sublicense agreement, Company will (i) prohibit the sublicensee from further sublicensing, except for a further sublicense limited to the right to manufacture and distribute a Licensed Product developed by the sublicensee, and (ii) require the sublicensee to comply with the terms and conditions of this Agreement other than the payment and reporting obligations of Company.

(b) Within thirty (30) days after Company enters into a sublicense agreement, Company will deliver to Rockefeller a complete and accurate copy of the entire sublicense agreement written in the English language. Rockefeller's receipt of the sublicense agreement, however, will constitute neither an approval of the sublicense nor a waiver of any right of Rockefeller or obligation of Company under this Agreement.

(c) In the event that company causes or experiences a bankruptcy event, all payments due to Company from its Affiliates or sublicensees under the sublicense agreement will, upon notice from Rockefeller to such Affiliate or sublicensee, become payable directly to Rockefeller for the account of Company. Upon receipt of any such funds, Rockefeller will remit to Company the amount by which such payments exceed the amounts owed by Company to Rockefeller.

(d) Company's execution of a sublicense agreement will not relieve Company of any of its obligations under this Agreement. Company is primarily liable to Rockefeller for any act or omission of an Affiliate or sublicensee of Company that would be a breach of this Agreement if performed or omitted by Company, and Company will be deemed to be in breach of this Agreement as a result of such act or omission.

2	FEES AND ROYALTIES

2.1 License Initiation Fee. In partial consideration of the License. Company will pay to Rockefeller on the Effective Date a non-refundable license initiation fee of Forty Thousand Dollars (S 40,000).

2.2 Minimum Royalties. In partial consideration of the License. Company will pay to Rockefeller, on each anniversary of the Effective Date, a minimum annual royalty of [***] Dollars ($[***]). Company's actual earned royalties payable to Rockefeller under Section 2.4 may be credited against this minimum annual royalty for the following four Quarters.

2.3 Progress Report. In addition, Company shall provide Rockefeller on each anniversary of the Effective Date with written progress reports discussing the development, evaluation, testing and commercialization of all Licensed Products.

2.4 Earned Royalties. In partial consideration of the License, Company will pay to Rockefeller a royalty of [***] Percent ([***] %) of Net Sales during the Quarter.

The term "Quarter" means each three-month period beginning on January 1, April 1, July 1 and October 1.

The term "Sale" means any bona fide transaction by Company or its sublicensees for which consideration is received or expected from an unaffiliated third party for the sale, use, lease, transfer or other disposition of a Licensed Product, and a sale is deemed completed at the time that Company or its sublicensees invoices, ships, or receives payment for a Licensed Product, whichever occurs first.

The term "Net Sales" means the consideration received from, or fair market value attributable to, each Sale, less Qualifying Costs directly attributable to a Sale and actually identified on the invoice and borne by Company or its sublicensees. Net Sales shall not include sales or transfer between Company and its Affiliates, unless the Licensed Product is consumed by the Affiliate. For purposes of determining Net Sales, the words "fair market value" mean the cash consideration that Company or its sublicensees would realize from an unrelated buyer in an arms length sale of an identical item sold in the same quantity and at the time and place of the transaction.

The term "Qualifying Costs" means: (a) customary discounts in the trade for quantity purchased, prompt payment or wholesalers and distributors; (b) credits or refunds for claims or returns that do not exceed the original invoice amount; (c) prepaid outbound transportation expenses and transportation insurance premiums; and (d) sales and use taxes and other fees imposed by a governmental agency.

2.5 Stacking Protection. If Company becomes obligated to pay royalties to third parties for technology necessary to develop or manufacture a Licensed Product and the aggregate royalty rate owed by Company to all parties (including Rockefeller) to manufacture and sell a Licensed Product exceeds fourteen percent (14%), then the royalty rate payable to Rockefeller under Section 2.4 for such Licensed Product will be reduced pro rata, along with all third party royalty rates, so as to reduce the maximum aggregate royalty rate to ten percent (10%). A reduction of the royalty rate in Section 2.4 for one Licensed Product will not affect the royalty rate for another Licensed Product. Furthermore, no royalty reduction for a Licensed Product will apply unless all third party licensors for the Licensed Product agree to their respective pro rata royalty reductions.

2.6 Payments Related to Combination Products. In the event that a Licensed Product is sold in combination with another product or products, which are not a Licensed Products, the amount of royalties and payments paid shall be based on the proportion of the value of such combination product reasonably attributable to the Licensed Product. In particular, if a Licensed Product contains or is designed to detect both microRNA sequences covered by a Valid Claim of Rockefeller Patent Rights and microRNA sequences that are not covered by a Valid Claim of Rockefeller Patent Rights, then Net Sales of such Licensed Product shall be multiplied by the ratio of (x) the number of microRNA sequences covered by a Valid Claim of Rockefeller Patent Rights in a given Licensed Product to (y) the total number of microRNA sequences included in such given Licensed Product to determine the portion of the value of the microRNA sequences in the combination product attributable to Rockefeller microRNA sequences.

2.7 Royalty Floor. Notwithstanding Sections 2.5 and 2.6, in no event will the royalty rate payable to Rockefeller under Section 2.4 for any Licensed Product be reduced to less than [***] percent ([***]%) of Net Sales.

2.8 Sublicense Fees. In partial consideration of the License, Company will pay to Rockefeller a sublicense fee of [***] percent ([***]%) of all payments and the fair market value of al other consideration of any kind received by Company from sublicensees during the Quarter, other than: (a) royalties paid to Company by a sublicensee based upon Sales or Net Sales by the sublicensee; (b) equity investments in Company by a sublicensee up to the amount of the fair market value of the equity purchased on the date of the investment; (c) loan proceeds paid to Company by a sublicensee in an arms-length, full recourse debt financing; and (d) future sponsored research funding paid to Company by a sublicensee in a bona fide transaction. Such sublicense fee sharing will be discountable in accordance with Section 2.6, however, in no event will the sublicense fee be reduced to less than [***] percent ([***]%) of the consideration received by the Company from the sublicensee.

2.9 Most Favored Licensee. If Rockefeller grants a license under the Rockefeller Patent Rights which will permit such licensee to manufacture or sell for any use within the scope of the license granted in this Agreement at a lower royalty rate than that provided in this Agreement, then Rockefeller will promptly notify Company of such license. The notice will include all material terms and conditions of such license, including degree of non-exclusivity, duration, field, territory, audit rights, all fees, and royalty rates, and extend to Company the lower royalty rates along with all of the material terms and conditions of such license. In the event that Company elects to take the royalty rates and the material terms and conditions of such noticed license, the royalty rate and all material terms and conditions of such noticed license shall apply to Company upon the date Company provides Rockefeller with its written notice of such election.

3	REPORTS AND PAYMENTS

3.1 Royalty Reports. Within sixty (60) days after the end of each Quarter following first commercial Sale of a Licensed Product, Company will deliver to Rockefeller a report, certified by the chief financial officer of Company, detailing the calculation of all royalties and fees due to Rockefeller for such Quarter. The report will include, at a minimum: (a) the number of Licensed Products involved in Sales, listed by product, by country; (b) gross consideration invoiced, billed or received for Sales in the Quarter; (c) Qualifying Costs, listed by category of cost; (d) Net Sales, listed by product, by country; (e) royalties and fees owed to Rockefeller, listed by category, by product, by country; and (f) any applicable credits resulting from royalty credits.

3.2 Payments. Company will pay all royalties due to Rockefeller under Section 2.4 within [***] days after the end of the Quarter in which the royalties or fees accrue.

3.3 Records. Company will maintain, and cause its Affiliates and sublicensee to maintain, complete and accurate books and records to verify Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement. The records for each Quarter will be maintained for at least five (5) years after submission of the applicable report required under Section 3.1.

3.4 Audit Rights. Upon reasonable prior written notice to Company, Company will provide Rockefeller accountants with access to all of the books and records required by Section 3.3 to conduct a review or audit of Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement. Access will be made available: (a) during normal business hours; (b) in a manner reasonably designed to facilitate Rockefeller's review or audit without unreasonable disruption to Company's business; and (c) no more than once each calendar year during the Term and for a period of five (5) years thereafter. Company will promptly pay to Rockefeller the amount of any underpayment determined by the review or audit plus accrued interest. If the review or audit determines that Company has underpaid any royalty payment by [***] percent ([***]%) or more, then Company will also promptly pay the costs and expenses of Rockefeller accountants in connection with the review or audit. In addition, once annual Sales of Licensed Products exceed [***] Dollars ($[***]), Company will conduct, at least once every two (2) years at its own expense, an independent audit of Sales, Net Sales, and all of the royalties, fees, and other payments payable under this Agreement. Promptly after completion of the audit, Company will provide to Rockefeller a copy of the report of the independent auditors.

3.5 Information Rights. Company will provide to Rockefeller a copy of each annual report, proxy statement, 10-K, 10-Q and other material reports filed with the U.S. Securities and Exchange Commission.

3.6 Currency. All dollar amounts referred to in this Agreement are expressed in United States dollars. All payments will be made in United States dollars. If Company receives payment from a third party in a currency other than United States dollars for which a royalty or fee is owed under this Agreement, then (a) the payment will be converted into United States dollars at the conversion rate for the foreign currency as published in the eastern edition of the Wall Street Journal as of the last business day of the Quarter in which the payment was received by Company, and (b) the conversion computation will be documented by Company in the applicable report delivered to Rockefeller under Section 3.1.

3.7 Place of Payment. All payments by Company are payable to "The Rockefeller University" and will be made to the following addresses:

By Electronic Transfer:	By Check:

JP Morgan Chase Bank 1166 Avenue of the Americas, 16^th Floor New York, NY 10036 Swift code: CHASUS33 Account #: [*] Routing #: [] Account Name: [] Reference: [*]	The Rockefeller University Office of Technology Transfer 502 Founders Hall 1230 York Avenue New York, NY 10065

3.8 Interest. All amounts that are not paid by Company when due will accrue interest from the date due until paid at a rate equal to [***] percent ([***]%) per month (or the maximum allowed by law, if less).

4	CONFIDENTIALITY AND USE OF ROCKEFELLER'S NAME

4.1 Rockefeller's Confidential Information. The term "Confidential Information" includes all technical information, inventions, developments, discoveries, software, know-how, methods, techniques, formulae, data, processes, and other proprietary ideas, whether or not patentable, that Rockefeller identifies as confidential or proprietary at the time it is delivered or communicated to Company.

4.2 Company's Obligation. Company will maintain in confidence and not disclose to any third party any Confidential Information. Company will use the Confidential Information only for the purposes of this Agreement. Company will ensure that Company's employees have access to Confidential Information only on a need to know basis and are obligated in writing to abide by Company's obligations under this Agreement. The obligations under this Section 4.2 will not apply to: (a) information that is known to Company or independently developed by Company prior to the time of disclosure, in each case where the Confidential Information is a specific microRNA sequence, to the extent evidenced by written records promptly disclosed to Rockefeller upon receipt of the Confidential Information; (b) information that is disclosed to Company by a third party that has the right to make such disclosure; (c) information that becomes patented, published or otherwise part of the public domain as a result of acts by Rockefeller or a third party obtaining such information as a matter of right; or (d) information that is required to be disclosed by order of United States governmental authority or a court of competent jurisdiction, provided that Company must use its best efforts to obtain confidential treatment of such information by such agency or court.

4.3 Disclaimer. Rockefeller is not obligated to accept any confidential information from Company, except for the reports required by Sections 2.3, 3.1 and 3.5. Rockefeller, acting through its Office of Technology Transfer and finance offices, will use its best efforts not to disclose to any third party outside of Rockefeller any confidential information of Company contained in those reports, subject to exceptions analogous to those contained in Section 4.2(a) - (d) above. Rockefeller bears no institutional responsibility for maintaining the confidentiality of any other information of Company. Company may elect to enter into confidentiality agreements with individual investigators at Rockefeller that comply with Rockefeller's internal policies.

4.4 Use of Rockefeller's Name. Company, its sublicensees, and their employees and agents may not use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Rockefeller or any Rockefeller school, organization, employee, student or representative, without the prior written consent of Rockefeller.

5	TERM AND TERMINATION

5.1 Term. This Agreement will commence on Effective Date and terminate upon the later of: (a) the expiration or abandonment of the last patent to expire or become abandoned of the Rockefeller Patent Rights; or (b) if no patent ever issues from the Rockefeller Patent Rights, ten (10) years after the first commercial sale of the first Licensed Product (as the case may be, the "Term").

5.2 Early Termination by Company. Company may terminate this Agreement at any time upon sixty (60) days prior written notice to Rockefeller after completing each of the following: (a) ceasing to make, have made, use, import, sell and offer for sale all Licensed Products, (b) terminating all sublicenses and causing all Affiliates and sublicensees to cease making, having made, using, importing, selling and offering for sale all Licensed Products; and (c) paying all amounts owed to Rockefeller under this Agreement through the date of termination.

5.3 Early Termination by Rockefeller. Rockefeller may terminate this Agreement if: (a) Company is more than thirty (30) days late in paying to Rockefeller any amounts owed under this Agreement and does not immediately pay Rockefeller in full within ten (10) days upon demand; or (b) Company or its Affiliates or sublicensees breaches this Agreement and does not cure the breach within forty-five (45) days after written notice of the breach.

5.4 Effect of Termination. Upon the termination of this Agreement for any reason: (a) the License terminates; (b) Company and its sublicensees will cease all making, having made, using, importing, selling and offering for sale all Licensed Products; (c) Company will pay to Rockefeller all amounts owed to Rockefeller through the date of termination under this Agreement; (c) Company will, at Rockefeller's request, return to Rockefeller all Confidential Information; and (d) in the case of termination under Section 5.3, all duties of Rockefeller and all rights (but not duties) of Company under this Agreement immediately terminate without further action required by either Rockefeller or Company.

5.5 Survival. Company's obligation to pay all amounts owed to Rockefeller under this Agreement will survive the termination of this Agreement for any reason. Articles 3, 4, 5, 8, 9 and Section 11.10 will survive the termination of this Agreement for any reason in accordance with their respective terms.

6	PATENT MAINTENANCE AND REIMBURSEMENT

6.1 Patent Maintenance. Rockefeller controls the preparation, prosecution and maintenance of the Rockefeller Patent Rights and the selection of patent counsel, with input from Company. Company will be copied on, and allowed to comment upon, all substantive issues in the patent prosecution.

6.2 Patent Reimbursement. Within thirty (30) days after the Effective Date, Company shall reimburse Rockefeller $[***] for a pro rata share of patent and licensing costs incurred prior to the Effective Date. Rockefeller will reimburse Company in the event the pro rata share is reduced due to Rockefeller's grant of additional licenses. Company shall pay a pro rata share, not to exceed [***]%, for all attorney fees, expenses, official fees and other charges incident to the preparation, prosecution, and maintenance of such patent applications and patents following the Effective Date.

7	INFRINGEMENT

7.1 Notice. Company and Rockefeller will notify each other promptly of any infringement of the Rockefeller Patent Rights that may come to their attention. Company and Rockefeller will consult each other in a timely manner concerning any appropriate response to the infringement.

7.2 Prosecution. Rockefeller may prosecute any infringement of the Rockefeller Patent Rights at Rockefeller's expense. If Rockefeller elects to prosecute such infringement, then financial recoveries will retained by Rockefeller in their entirety.

7.3 Intervention. Rockefeller reserves the right to request Company to join in any litigation under Section 7.2. If Company elects to participate in any such litigation, then financial recoveries from any such litigation will be shared between Company and Rockefeller in proportion with their respective shares of the aggregate litigation expenditures.

7.4 Company Prosecution. If Rockefeller does not prosecute any infringement of the Rockefeller Patent Rights, Company may prosecute any infringement of the Rockefeller Patent Rights at Company's expense. Company must not settle or compromise any such litigation in a manner that imposes any obligations or restrictions on Rockefeller or grants any rights to the Rockefeller Patent Rights without Rockefeller's prior written permission. Financial recoveries from any such litigation will be: (a) first, applied to reimburse Company for its litigation expenditures; and (b) second, as to any remainder, retained by Company, but treated as Net Sales for the purpose of determining the royalties due to Rockefeller under Section 2.4.

7.5 Cooperation. In any litigation under this Article 7, either party, at the request and expense of the other party, will cooperate to the fullest extent reasonably possible. This Section 7.5 will not be construed to require either party to undertake any activities, including legal discovery, at the request of any third party, except as may be required by lawful process of a court of competent jurisdiction.

8	DISCLAIMER OF WARRANTIES; LIMITATION OF LIABILITIES

8.1 Rockefeller and Company each represent that, to the best of their knowledge as of the Effective Date, they have the legal right and authority to enter into this Agreement and to perform all obligations hereunder. Rockefeller further represents that, to the best of the knowledge of the Office of Technology Transfer as of the Effective Date, the patent applications listed on Exhibit A have been assigned to Rockefeller by the inventors named therein and Rockefeller owns all right, title, and interest of such inventors in such patent applications.

8.2 THE ROCKEFELLER PATENT RIGHTS, ROCKEFELLER TECHNICAL INFORMATION, LICENSED PRODUCTS, AND ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN "AS IS" BASIS. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, ROCKEFELLER MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE. ROCKEFELLER WILL NOT BE LIABLE TO COMPANY, ITS SUCCESORS OR ASSIGNS, OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM: ARISING FROM COMPANY'S USE OF THE ROCKEFELLER PATENT RIGHTS, ROCKEFELLER TECHNICAL INFORMATION, LICENSED PRODUCTS OR ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT; ARISING FROM THE DEVELOPMENT, TESTING, MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS; OR FOR LOST PROFITS, BUSINESS INTERRUPTION, OR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND.

9	INDEMNIFICATION

THE ROCKEFELLER UNIVERSITY		ROSETTA GENOMICS, LTD.

By:	/s/ John Tooze	By:	/s/ Tamir Kazaz
Name:	John Tooze	Name:	Tamir Kazaz
Title:	Vice President	Title:	CEO
	Scientific and Facilities Operations

Address:		Address:

	The Rockefeller University Office of Technology Transfer 1230 York Avenue 502 Founders Hall New York, NY 10065	Rosetta Genomics, Ltd. 675 US Highway One Suite B119 North Brunswick, NJ 08902

Required copy to:

	The Rockefeller University Office of General Counsel 1230 York Avenue, Box 81 New York, NY 10065